AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31077827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (maintenance)
Number of subjects: 1157
Study 31077827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (any dosage)
Number of subjects: 1157
Study 28017170 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30mg·kg‐1)
Number of subjects: 56
Study 28017170 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2mg·kg‐1)
Number of subjects: 56
Study 28017170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 26237643 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 60
Study 26237643 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite
Number of subjects: 60
Study 23478193 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630 (3 × 30 drops/day for 24 weeks)
Number of subjects: 200
Study 23478193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 23478193 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 200
Study 21820770 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 167
Study 21820770 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula
Number of subjects: 167
Study 21820770 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 167
Study 21820770 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 167
Study 21820770 — intervention group
Group type: COMPARATOR
Intervention: Overall results
Number of subjects: 167
Study 19590475 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 59
Study 19590475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (10 mg daily increment over 1 week to 50 mg)
Number of subjects: 59
Study 19590475 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TENS and Nortriptyline
Number of subjects: 59
Study 17334477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg once a week for 6 weeks)
Number of subjects: 50
Study 17334477 — intervention group
Group type: COMPARATOR
Intervention: Diphereline (3.75 mg 4 times every 28 days)
Number of subjects: 50
Study 14973304 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg p.o. on day 1 and 80 mg p.o. on days 2 and 3
Number of subjects: 24
Study 14973304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11253520 — intervention group
Group type: EXPERIMENTAL
Intervention: Münster Posterior Doublerod‐System (MPDS)
Number of subjects: 45
Study 11253520 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage ventro-dorsal procedure in combination with VDS and MPDS
Number of subjects: 45
Study 9477905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice (1,400 ppm)
Number of subjects: 115
Study 9477905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (1,400 ppm)
Number of subjects: 115
Study 9477905 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 115
Study 7886279 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk angle at 60 degrees
Number of subjects: 16
Study 7886279 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk angle at 90 degrees
Number of subjects: 16
Study 7886279 — intervention group
Group type: COMPARATOR
Intervention: Trunk angle at 120 degrees
Number of subjects: 16
Study 3367172 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (urged to have annual multiphasic health checkups)
Number of subjects: 10713
Study 3367172 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonurged subjects)
Number of subjects: 10713
Study 30197040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG vaccine prior to standard intravesical BCG
Number of subjects: 0
Study 30197040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokyo-172 BCG strain
Number of subjects: 0
Study 27998549 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal handoff approach
Number of subjects: 5157
Study 27998549 — intervention group
Group type: COMPARATOR
Intervention: Focused handoff process
Number of subjects: 5157
Study 26210166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosaprepitant 150 mg (NK1 group)
Number of subjects: 38
Study 26210166 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg (ONS group)
Number of subjects: 38
Study 24283179 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (LNG‐IUD)
Number of subjects: 40
Study 24283179 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 20 mg/daily for ten days
Number of subjects: 40
Study 21210812 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic DNA evidence presented without case context
Number of subjects: 0
Study 21210812 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic DNA evidence presented within the context of a criminal case
Number of subjects: 0
Study 18080059 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (Revia) or acamprosate (Campral) or both medications and/or placebos in combination with medical management (MM), with or without combined behavioral intervention (CBI)
Number of subjects: 1383
Study 18080059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 1383
Study 18080059 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1383
Study 18080059 — intervention group
Group type: COMPARATOR
Intervention: CBI without MM or pills
Number of subjects: 1383
Study 18080059 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate
Number of subjects: 1383
Study 17318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (Telm) 80 mg + Rosiglitazone (RSG) 4 mg
Number of subjects: 40
Study 17318795 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (Aml) 10 mg + Rosiglitazone (RSG) 4 mg
Number of subjects: 40
Study 14706485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mobile phone exposure
Number of subjects: 12
Study 14706485 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 12
Study 10673490 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom promotion intervention
Number of subjects: 1382
Study 10673490 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1382
Study 10673490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1382
Study 9175946 — intervention group
Group type: EXPERIMENTAL
Intervention: 97% light filtering goggles for a minimum of four weeks or until the infant reached 31 weeks postmenstrual age
Number of subjects: 61
Study 9175946 — intervention group
Group type: EXPERIMENTAL
Intervention: 97% light filtering goggles
Number of subjects: 61
Study 9175946 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 1532336 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly amorolfine 5% nail lacquer
Number of subjects: 456
Study 1532336 — intervention group
Group type: COMPARATOR
Intervention: Once weekly amorolfine 5% nail lacquer
Number of subjects: 456
Study 4065179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) + danazol
Number of subjects: 0
Study 4065179 — intervention group
Group type: COMPARATOR
Intervention: Aminoglutethimide (AG) alone
Number of subjects: 0
Study 31566843 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week interval group
Number of subjects: 330
Study 31566843 — intervention group
Group type: COMPARATOR
Intervention: 12-week interval group
Number of subjects: 330
Study 29659913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 mg/day initially, adjusted as necessary)
Number of subjects: 183
Study 29659913 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone hydrochloride (10 mg/day initially, adjusted as necessary)
Number of subjects: 183
Study 29659913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 183
Study 27801825 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement containing 600 mg of α‐lipoic acid, 165 mg of L‐carnosin, 7.5 mg of zinc, and vitamins of group B
Number of subjects: 105
Study 23212928 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral stress management intervention
Number of subjects: 0
Study 23212928 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 23259414 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane seeded with autologous gingival fibroblasts (CM+GF)
Number of subjects: 11
Study 23259414 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (CM)
Number of subjects: 11
Study 19929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/d, titrated to 300 mg/day)
Number of subjects: 426
Study 19929980 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 12.5 mg/d, titrated to 25 mg/day)
Number of subjects: 426
Study 19929980 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 426
Study 19929980 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 426
Study 18947161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-Ketorolac
Number of subjects: 55
Study 18947161 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-Placebo
Number of subjects: 55
Study 16636232 — intervention group
Group type: EXPERIMENTAL
Intervention: IV recombinant tissue plasminogen activator (rt‐PA) 0.9 mg/kg
Number of subjects: 616
Study 16636232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 616
Study 14675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0
Study 14675576 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Number of subjects: 0
Study 10807491 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 32
Study 10807491 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 375 mg/day
Number of subjects: 32
Study 10807491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 32
Study 10807491 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg/day
Number of subjects: 32
Study 9085388 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 9085388 — intervention group
Group type: COMPARATOR
Intervention: Annual tuberculin testing plus isoniazid (INH) preventive therapy
Number of subjects: 0
Study 8138865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral therapy (relaxation training, temperature biofeedback, cognitive training)
Number of subjects: 41
Study 8138865 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 41
Study 8138865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral therapy
Number of subjects: 41
Study 8138865 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature biofeedback
Number of subjects: 41
Study 3752471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsator syringes
Number of subjects: 50
Study 3752471 — intervention group
Group type: COMPARATOR
Intervention: Radiometer B 129 syringes
Number of subjects: 50
Study 30222541 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed-fit using REM to NAL-NL2
Number of subjects: 24
Study 30222541 — intervention group
Group type: COMPARATOR
Intervention: First-fit
Number of subjects: 24
Study 26698911 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g plus 200 μg folic acid twice a day)
Number of subjects: 220
Study 26698911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 μg folic acid twice a day)
Number of subjects: 220
Study 24945426 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) concentrations
Number of subjects: 307
Study 24945426 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in ITA° value (reflectance colorimeter measurement of skin color)
Number of subjects: 307
Study 24945426 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/ethnicity prediction of 25OHD
Number of subjects: 307
Study 23742728 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 23 mg/d
Number of subjects: 0
Study 23742728 — intervention group
Group type: COMPARATOR
Intervention: donepezil 10 mg/d
Number of subjects: 0
Study 20826962 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.2 mg/Kg
Number of subjects: 60
Study 20826962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg/Kg
Number of subjects: 60
Study 20826962 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg/Kg
Number of subjects: 60
Study 20826962 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/Kg
Number of subjects: 60
Study 20826962 — intervention group
Group type: COMPARATOR
Intervention: All groups (Etomidate, Midazolam, Thiopentone, Propofol)
Number of subjects: 60
Study 18796471 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenous bolus after third unsuccessful shock)
Number of subjects: 0
Study 18796471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 16155274 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d
Number of subjects: 275
Study 16155274 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Zn/d
Number of subjects: 275
Study 16155274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 14693308 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled, disposable pen (FlexPen)
Number of subjects: 121
Study 14693308 — intervention group
Group type: COMPARATOR
Intervention: Vial/syringe
Number of subjects: 121
Study 14693308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 121
Study 11949772 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced mixture (B)
Number of subjects: 12
Study 11949772 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine and tyrosine deficient mixture (PT‐)
Number of subjects: 12
Study 10078604 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HAV vaccination (25 units) at 0 and 24 weeks (Group 1)
Number of subjects: 55
Study 10078604 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of HAV vaccination (25 units) at 0, 2, and 24 weeks (Group 2)
Number of subjects: 55
Study 7668311 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (2 micrograms/kg, subcutaneously, every 8 hours)
Number of subjects: 8
Study 7668311 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 8
Study 7668311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1869643 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release styrene-divinylbenzene polymer system containing benzoyl peroxide
Number of subjects: 0
Study 1869643 — intervention group
Group type: COMPARATOR
Intervention: Topical lotion with freely dispersed benzoyl peroxide
Number of subjects: 0
Study 1869643 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing entrapped benzoyl peroxide
Number of subjects: 0
Study 7267678 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrotalcite/dimethicone suspension
Number of subjects: 36
Study 7267678 — intervention group
Group type: COMPARATOR
Intervention: magnesium hydroxide/aluminum hydroxide suspension
Number of subjects: 36
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories
Number of subjects: 91
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories
Number of subjects: 91
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories after halothane anaesthesia
Number of subjects: 91
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories after enflurane anaesthesia
Number of subjects: 91
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories after enflurane anaesthesia
Number of subjects: 91
Study 6741447 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories after halothane anaesthesia
Number of subjects: 91
Study 29843528 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about potentially 'therapeutic' topics
Number of subjects: 68
Study 29843528 — intervention group
Group type: COMPARATOR
Intervention: Writing about daily events
Number of subjects: 68
Study 27852684 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day resveratrol (resVida)
Number of subjects: 17
Study 23617557 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step method (2-h, 75 g oral glucose tolerance test)
Number of subjects: 786
Study 23617557 — intervention group
Group type: COMPARATOR
Intervention: Two-step method (50 g glucose challenge test followed by 100 g OGTT)
Number of subjects: 786
Study 23617557 — intervention group
Group type: COMPARATOR
Intervention: GCT-negative group
Number of subjects: 786
Study 23617557 — intervention group
Group type: COMPARATOR
Intervention: C&C-negative group
Number of subjects: 786
Study 23588128 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered paper-and-pencil questionnaire measuring perceived risk for STIs
Number of subjects: 1192
Study 21174921 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone
Number of subjects: 450
Study 21174921 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone
Number of subjects: 450
Study 21174921 — intervention group
Group type: COMPARATOR
Intervention: No steroids (Control group)
Number of subjects: 450
Study 19094438 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg levobupivacaine 0.5% mixed with 25 microg fentanyl (group LF)
Number of subjects: 40
Study 19094438 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg levobupivacaine 0.5% (group L)
Number of subjects: 40
Study 16627843 — intervention group
Group type: EXPERIMENTAL
Intervention: Microphone announcement
Number of subjects: 1000
Study 16627843 — intervention group
Group type: COMPARATOR
Intervention: Telephone announcement
Number of subjects: 1000
Study 16627843 — intervention group
Group type: COMPARATOR
Intervention: Computer announcement
Number of subjects: 1000
Study 14531504 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (seminars, outreach visits, reminders, CME small group training)
Number of subjects: 727
Study 14531504 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 727
Study 10924301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium (10.3 mmol)
Number of subjects: 301
Study 10924301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 10924301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol and oral magnesium
Number of subjects: 301
Study 10924301 — intervention group
Group type: COMPARATOR
Intervention: Sotalol and placebo
Number of subjects: 301
Study 8880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 80 micrograms.kg-1 during N2O-O2-halothane anaesthesia
Number of subjects: 32
Study 8880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 100 micrograms.kg-1 during N2O-O2-opioid anaesthesia
Number of subjects: 32
Study 8880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 45 micrograms.kg-1 with glycopyrrolate
Number of subjects: 32
Study 8880817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 32
Study 1529944 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6827
Study 1529944 — intervention group
Group type: COMPARATOR
Intervention: Prevention trial
Number of subjects: 6827
Study 1529944 — intervention group
Group type: COMPARATOR
Intervention: Treatment trial
Number of subjects: 6827
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm milk with iron supplementation (2 mg/kg/day)
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature human milk with iron supplementation (2 mg/kg/day)
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with iron supplementation (2 mg/kg/day)
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm milk without iron supplementation
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature human milk without iron supplementation
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula without iron supplementation
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm milk with routine multivitamin supplementation
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature human milk with routine multivitamin supplementation
Number of subjects: 36
Study 3981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with routine multivitamin supplementation
Number of subjects: 36
Study 31960705 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Number of subjects: 54
Study 31960705 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study 29383426 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-Antimony colloid (Group-1)
Number of subjects: 78
Study 29383426 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-Sulphur colloid (Group-2)
Number of subjects: 78
Study 26902092 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of dried plum
Number of subjects: 48
Study 26902092 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of dried plum
Number of subjects: 48
Study 26902092 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 24525660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/d)
Number of subjects: 164
Study 24525660 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 mg/d)
Number of subjects: 164
Study 24525660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Tianeptine and Escitalopram
Number of subjects: 164